Is MRK a buy, hold, or sell?
MRK carries a valuation grade of Strong Buy. The trailing P/E of 32.1 sits 46% above the Healthcare sector median of 22.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $125–$213 — implying a +49% margin of safety at the current price of $113.87. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 12% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a 13.2% earnings surprise. Analyst estimate revisions are trending upward.
What are MRK's key risk factors?
With a beta of 0.22, MRK exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -8.3% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 0.8% of total portfolio loss in the worst 5% of months. Net margins of 13.6% fall below the Healthcare sector average of 18%, suggesting margin pressure. Return on equity of 18.9% suggests solid capital efficiency. Leverage is moderate with debt-to-equity at 107%.
At 0.54, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied and realized volatility are roughly aligned at 33.2% and 34.0% respectively. Insider transactions show net buying of $30.2M over the trailing period, a signal often associated with management confidence. Short interest is low at 1.2% of float, suggesting limited bearish conviction.
How does MRK fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — MRK carries a beta of 0.22, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, MRK shows the strongest co-movement with PFE (0.56), JNJ (0.47), ABBV (0.42). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The MRK analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning MRK’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
